Bio


Joshua Isaac Leaston is a MD candidate with a concentration in bioengineering and application in Neuroscience, behavior, and cognition in the Stanford University School of Medicine. A member of the entering class of 2021, Joshua holds a degree in Neuroscience with a minor in Health Science and has received various academic excellence awards and scholarships.

His research interests include the development of quantitative neuroimaging methodologies for neurosurgical and radiological outcome improvement. He has also received a research fellowship from a Boston based neuroimaging organization and MedScholars funding for his research on neuroimaging methodologies. This is further augmented by a Stanford-based seed grant, enabling him to delve into the investigation of disparities in outcomes of image-guided procedures within high-risk patient populations nationwide.

In addition to his academic pursuits, he is also the co-founder of a company focused on addressing disparities in skin cancer through advanced imaging, which has been recognized through the Stanford Biodesign NEXT award and eWEAR.

Further, he is dedicated to raising awareness around the intersectionality between the unhoused community and medicine. Joshua co-founded a nonprofit dedicated to supporting unhoused individuals, where he has raised funding to sustainably support the cause since 2019.

Joshua has also demonstrated his dedication to advancing science and medicine through several presentations, including a talk at Tufts Medicine on barriers in medical school enrollment for minorities and a presentation at Northeastern University on "How to Build a Nonprofit." He has presented at conferences such as Rise, KTGF, SPINE, RSNA, ACR, ASNR, AANS, ISMRM, and the AMEC-SNMA conference, and has published in peer-reviewed journals.

In conclusion, Joshua Isaac Leaston's academic excellence, research contributions, and dedication to social causes showcase his strong potential to become a compassionate and impactful physician scientist.

Education & Certifications


  • Bachelor of Science, Northeastern University (2020)
  • Bachelor of Science, Northeastern University, Neuroscience (2020)

All Publications


  • Opioid usage in lumbar disc herniation patients with nonsurgical, early, and late surgical treatments. World neurosurgery Zhou, Z., Jin, M. C., Jensen, M. R., Barros Guinle, M. I., Ren, A., Agarwal, A. A., Leaston, J., Ratliff, J. K. 2023

    Abstract

    Assess opioid usage in surgical and non-surgical patients with lumbar disc herniation receiving different treatment approaches and timing.Individuals with newly diagnosed lumbar intervertebral disc without myelopathy were queried from Optum Clinformatics DataMart. Patients were categorized into 3 cohorts: nonsurgical, early surgery, and late surgery. Early surgery cohort patients had surgery within 30-days post-diagnosis; late surgery cohort patients had surgery after 30 days but before 1-year post-diagnosis. The index date was defined as the diagnosis date for nonsurgical patients, and the initial surgery date for surgical patients. The primary outcome was the average daily opioid morphine milligram equivalent (MME) prescribed. Additional outcomes included the percentage of opioid-using patients and cumulative opioid burden.A total of 573,082 patients met inclusion criteria: 533,226 patients received nonsurgical treatments, 22,312 patients received early surgery, and 17,544 patients received late surgery. Both surgical cohorts experienced a "post-surgical hump" of opioid usage, which then sharply declined and gradually plateaued, with daily opioid MME consistently lower in the early as opposed to late surgery cohort. The early surgery cohort also consistently had a lower prevalence of opioid-using patients than the late surgery cohort. Patients receiving nonsurgical demonstrated the highest one-year post-index cumulative opioid burden, and the early surgery cohort consistently had lower cumulative opioid MME than the late surgery cohort.Early surgery in lumbar disc herniation patients is associated with lower long-term average daily MME, incidence of opioid use, and one-year cumulative MME burden compared to nonsurgical and late surgery treatment approaches.

    View details for DOI 10.1016/j.wneu.2023.02.029

    View details for PubMedID 36775237

  • Treating mild repetitive mild head injury with a vasopressin V1a receptor antagonist: evidence of suppressed microglia activation and regional cerebral blood volume Under Review Bens, N., Leaston, J., Kulkarni, P., Hightower, R., Prom, S., O'Hare, N., Ebong, E., Simon, N., Brownstein, M., Gharagouzloo, C., Ferris, C. 2023
  • Do We Swallow the Waste From Our Brain? Frontiers in neuroscience Leaston, J., Kulkarni, P., Gharagouzloo, C., Qiao, J., Bens, N., Ferris, C. F. 2021; 15: 763780

    Abstract

    Ferumoxytol, an iron oxide nanoparticle, was infused into the lateral cerebroventricle of awake rats to follow its movement and clearance from the brain using magnetic resonance imaging. Within minutes the contrast agent could be observed accumulating in the subarachnoid space, nasal cavity, nasal pharynx, and soft palate at the back of the throat. In a subsequent study fluorescent quantum dots were infused into the brain of rats and within 15 min could be observed in the esophagus using microscopy. These imaging studies clearly show that these large nanoparticle tracers (∼20 nm in diameter) leave the brain through the nasal cavity and end up in the gut. There are numerous studies going back decades reporting the clearance of tracers put directly into the brain. While these studies show the slow accumulation of trace in the blood and lymphatics, they report only accounting for less than 50% of what was originally put in the brain.

    View details for DOI 10.3389/fnins.2021.763780

    View details for PubMedID 34887724

    View details for PubMedCentralID PMC8649892

  • Quantitative Imaging of Blood-Brain Barrier Permeability Following Repetitive Mild Head Impacts. Frontiers in neurology Leaston, J., Qiao, J., Harding, I. C., Kulkarni, P., Gharagouzloo, C., Ebong, E., Ferris, C. F. 2021; 12: 729464

    Abstract

    This was an exploratory study designed to evaluate the feasibility of a recently established imaging modality, quantitative ultrashort time-to-echo contrast enhanced (QUTE-CE), to follow the early pathology and vulnerability of the blood brain barrier in response to single and repetitive mild head impacts. A closed-head, momentum exchange model was used to produce three consecutive mild head impacts aimed at the forebrain separated by 24 h each. Animals were measured at baseline and within 1 h of impact. Anatomical images were collected to assess the extent of structural damage. QUTE-CE biomarkers for BBB permeability were calculated on 420,000 voxels in the brain and were registered to a bilateral 3D brain atlas providing site-specific information on 118 anatomical regions. Blood brain barrier permeability was confirmed by extravasation of labeled dextran. All head impacts occurred in the absence of any structural brain damage. A single mild head impact had measurable effects on blood brain barrier permeability and was more significant after the second and third impacts. Affected regions included the prefrontal ctx, basal ganglia, hippocampus, amygdala, and brainstem. Our findings support the concerns raised by the healthcare community regarding mild head injuries in participants in organized contact sports and military personnel in basic training and combat.

    View details for DOI 10.3389/fneur.2021.729464

    View details for PubMedID 34659094

    View details for PubMedCentralID PMC8515019

  • Neurovascular imaging with QUTE-CE MRI in APOE4 rats reveals early vascular abnormalities. PloS one Leaston, J., Ferris, C. F., Kulkarni, P., Chandramohan, D., van de Ven, A. L., Qiao, J., Timms, L., Sepulcre, J., El Fakhri, G., Ma, C., Normandin, M. D., Gharagouzloo, C. 2021; 16 (8): e0256749

    Abstract

    Cerebrovascular abnormality is linked to Alzheimer's disease and related dementias (ADRDs). ApoE-Ɛ4 (APOE4) is known to play a critical role in neurovascular dysfunction, however current medical imaging technologies are limited in quantification. This cross-sectional study tested the feasibility of a recently established imaging modality, quantitative ultra-short time-to-echo contrast-enhanced magnetic resonance imaging (QUTE-CE MRI), to identify small vessel abnormality early in development of human APOE4 knock-in female rat (TGRA8960) animal model. At 8 months, 48.3% of the brain volume was found to have significant signal increase (75/173 anatomically segmented regions; q<0.05 for multiple comparisons). Notably, vascular abnormality was detected in the tri-synaptic circuit, cerebellum, and amygdala, all of which are known to functionally decline throughout AD pathology and have implications in learning and memory. The detected abnormality quantified with QUTE-CE MRI is likely a result of hyper-vascularization, but may also be partly, or wholly, due to contributions from blood-brain-barrier leakage. Further exploration with histological validation is warranted to verify the pathological cause. Regardless, these results indicate that QUTE-CE MRI can detect neurovascular dysfunction with high sensitivity with APOE4 and may be helpful to provide new insights into health and disease.

    View details for DOI 10.1371/journal.pone.0256749

    View details for PubMedID 34449808

    View details for PubMedCentralID PMC8396782

  • Lumbar puncture outcomes in children with psychiatric history Leaston, J., Alananzeh, R., Abuhasan, Y., Al-Hajjiri, H., Agarwal, A. A. 2024
  • Analyzing the Impact of Educational Funding on Adolescent Mental Health: Correlations with Anxiety, Depression, and Suicide Rates in the United States Alananzeh, R., Al-Hajjiri, H., Abuhasan, Y., Leaston , J. 2024
  • Health-Related Outcomes of Image-Guided and Non-Image-Guided Lumbar Punctures in Diverse Patient Populations American Society of Neuroradiology Leaston, J., Nguyen, H., Agarwal, A. A., Iv, M. 2024
  • Psychological Health Outcomes of Unhoused Adolescents: A Rapid Review of Descriptive Epidemiology Klingenstein Third Generation Foundation Alananzeh, R., Abuhasan, Y., Al-Hajjiri, H., Etemadi, M., Masri, S., Maaita, H., Constantin, V., Leaston, J. 2023
  • Evaluating Comorbidity Index Performance in Patients Undergoing Spinal Fusion Procedures Stratified by Race American Association of Neurological Surgeons Leaston, J., Mittal, A., Jin, M., Dadey, D., Ratliff, J. 2023
  • Assessing the impact of patient's neighborhood on the ability of comorbidity scores to predict reoperation probability Spine Summit Leaston, J., Mittal, A., Jin, M., Dadey, D., Ratliff, J. 2023
  • Spinal decompression outcomes in children with psychiatric consultation history Klingenstein Third Generation Foundation Leaston, J., Kishore, A. 2023
  • TrueTone: A Digital Solution for Personalized Sunscreen Based on Your Skin Type eWEAR Annual Meeting Symposium 2023 Leaston, J. 2023
  • Predicting neurodevelopmental outcomes in premature infants with deep learning 37th Stanford Medical Student Research Symposium Leaston, J., Yeom, K. 2022